Valuation: BioNTech SE

Market Cap 2.16TCr 2.43TCr 2.02TCr 1.84TCr 3.47TCr 2,33800Cr 3.5TCr 24TCr 9.46TCr 1,19500Cr 9.13TCr 8.93TCr 3,83600Cr P/E 2026 *
-15.1x
P/E 2027 * -15.8x
Enterprise Value 1.02TCr 1.15TCr 955.79Cr 871.17Cr 1.64TCr 1,10800Cr 1.66TCr 12TCr 4.48TCr 57TCr 4.33TCr 4.23TCr 1,81800Cr EV / Sales 2026 *
5.67x
EV / Sales 2027 * 6.39x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-15.11%+2.41% - - 2.43TCr
+4.16%+3.04%+49.37%+94.17% 7.44TCr
-3.11%-3.53%+21.92%+74.60% 5.93TCr
+0.89%-0.63%+4.28%+34.51% 4.71TCr
-0.94%-4.28%+26.66%+33.49% 4.29TCr
0.00%+0.08%+348.88%+683.87% 4.41TCr
-1.40%-2.03%+2.42%+98.06% 4.08TCr
-0.54%+2.93%+9.50%+50.41% 3.08TCr
-2.68%+5.11%+33.11%+19.50% 2.93TCr
+1.24%-6.78%-28.12%+332.95% 2.37TCr
Average -0.01%-0.64%+52.00%+157.95% 4.36TCr
Weighted average by Cap. +0.15%-0.40%+57.10%+149.55%

Financials

2026 *2027 *
Net sales 180.69Cr 203.36Cr 168.64Cr 153.71Cr 289.9Cr 20TCr 292.6Cr 2.04TCr 790.84Cr 9.99TCr 763.53Cr 746.95Cr 32TCr 181.1Cr 203.83Cr 169.03Cr 154.07Cr 290.57Cr 20TCr 293.27Cr 2.05TCr 792.66Cr 10TCr 765.29Cr 748.67Cr 32TCr
Net income -137.67Cr -154.94Cr -128.49Cr -117.11Cr -220.88Cr -15TCr -222.93Cr -1.55TCr -602.54Cr -7.61TCr -581.73Cr -569.11Cr -24TCr -131.04Cr -147.49Cr -122.31Cr -111.48Cr -210.25Cr -14TCr -212.2Cr -1.48TCr -573.55Cr -7.25TCr -553.74Cr -541.72Cr -23TCr
Net Debt -1.14TCr -1.28TCr -1.06TCr -967.13Cr -1.82TCr -1,23000Cr -1.84TCr -13TCr -4.98TCr -63TCr -4.8TCr -4.7TCr -2,01800Cr -1TCr -1.13TCr -935.97Cr -853.1Cr -1.61TCr -1,08500Cr -1.62TCr -11TCr -4.39TCr -55TCr -4.24TCr -4.15TCr -1,78000Cr
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-